Adlai Nortye Ltd. (ANL)

NASDAQ: ANL · IEX Real-Time Price · USD
3.400
-0.120 (-3.41%)
At close: Jul 19, 2024, 4:00 PM
3.500
+0.100 (2.94%)
After-hours: Jul 19, 2024, 4:00 PM EDT
-3.41%
Market Cap 57.77M
Revenue (ttm) 5.00M
Net Income (ttm) -104.87M
Shares Out 16.99M
EPS (ttm) -7.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 615
Open 3.409
Previous Close 3.520
Day's Range 3.400 - 3.430
52-Week Range 3.010 - 19.300
Beta n/a
Analysts Buy
Price Target n/a
Earnings Date Aug 13, 2024

About ANL

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recur... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 29, 2023
Employees 127
Stock Exchange NASDAQ
Ticker Symbol ANL
Full Company Profile

Financial Performance

Financial Statements

News

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focu...

2 months ago - GlobeNewsWire

Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focu...

2 months ago - GlobeNewsWire

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company fo...

4 months ago - GlobeNewsWire

Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company foc...

8 months ago - GlobeNewsWire

Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a global clinical-stage biotechnology comp...

9 months ago - GlobeNewsWire

Adlai Nortye Ltd. Announces Closing of Initial Public Offering

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company foc...

10 months ago - GlobeNewsWire

Adlai Nortye Ltd. Announces Pricing of Initial Public Offering

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company fo...

10 months ago - GlobeNewsWire

Cancer treatment company Adlai Nortye sets terms in IPO

Adlai Nortye Ltd. said late Thursday it plans to offer three million American depositary shares at an estimated price of $22 to $26 a share in its initial public offering on the Nasdaq under the symbo...

1 year ago - Market Watch